| Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer G Valabrega, F Montemurro, M Aglietta Annals of oncology 18 (6), 977-984, 2007 | 823 | 2007 |
| Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging L Martincich, F Montemurro, G De Rosa, V Marra, R Ponzone, S Cirillo, ... Breast cancer research and treatment 83, 67-76, 2004 | 302 | 2004 |
| Correlations between diffusion-weighted imaging and breast cancer biomarkers L Martincich, V Deantoni, I Bertotto, S Redana, F Kubatzki, I Sarotto, ... European radiology 22, 1519-1528, 2012 | 271 | 2012 |
| Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm … F Montemurro, S Delaloge, CH Barrios, R Wuerstlein, A Anton, E Brain, ... Annals of Oncology 31 (10), 1350-1358, 2020 | 250 | 2020 |
| Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2× 2 factorial, randomised phase 3 trial L Del Mastro, S De Placido, P Bruzzi, M De Laurentiis, C Boni, ... The Lancet 385 (9980), 1863-1872, 2015 | 200 | 2015 |
| TGFα expression impairs Trastuzumab-induced HER2 downregulation G Valabrega, F Montemurro, I Sarotto, A Petrelli, P Rubini, C Tacchetti, ... Oncogene 24 (18), 3002-3010, 2005 | 179 | 2005 |
| Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy F Montemurro, M Donadio, M Clavarezza, S Redana, ME Jacomuzzi, ... The oncologist 11 (4), 318-324, 2006 | 168 | 2006 |
| Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications F Montemurro, S Di Cosimo, G Arpino Annals of Oncology 24 (11), 2715-2724, 2013 | 167 | 2013 |
| Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity F Montemurro, G Valabrega, M Aglietta Expert opinion on biological therapy 7 (2), 257-268, 2007 | 141 | 2007 |
| Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer C Peraldo-Neia, G Migliardi, M Mello-Grand, F Montemurro, R Segir, ... BMC cancer 11, 1-12, 2011 | 130 | 2011 |
| Metastatic breast cancer subtypes and central nervous system metastases C Aversa, V Rossi, E Geuna, R Martinello, A Milani, S Redana, ... The Breast 23 (5), 623-628, 2014 | 127 | 2014 |
| Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives A Milani, D Sangiolo, F Montemurro, M Aglietta, G Valabrega Annals of oncology 24 (7), 1740-1748, 2013 | 105 | 2013 |
| Moderate Immunohistochemical Expression of HER-2 (2+) Without HER-2 Gene Amplification Is a Negative Prognostic Factor in Early Breast Cancer V Rossi, I Sarotto, F Maggiorotto, P Berchialla, F Kubatzki, N Tomasi, ... The Oncologist 17 (11), 1418-1425, 2012 | 100 | 2012 |
| Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: primary results from the KAMILLA study cohort 1 F Montemurro, P Ellis, A Anton, R Wuerstlein, S Delaloge, J Bonneterre, ... European journal of cancer 109, 92-102, 2019 | 90 | 2019 |
| Neoadjuvant or adjuvant chemotherapy in early breast cancer? F Montemurro, I Nuzzolese, R Ponzone Expert opinion on pharmacotherapy 21 (9), 1071-1082, 2020 | 84 | 2020 |
| Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial S De Placido, C Gallo, M De Laurentiis, G Bisagni, G Arpino, MG Sarobba, ... The Lancet Oncology 19 (4), 474-485, 2018 | 82 | 2018 |
| Hormone‐receptor expression and activity of trastuzumab with chemotherapy in HER2‐positive advanced breast cancer patients F Montemurro, V Rossi, M Cossu Rocca, R Martinello, E Verri, S Redana, ... Cancer 118 (1), 17-26, 2012 | 82 | 2012 |
| Relationship between DCE-MRI morphological and functional features and histopathological characteristics of breast cancer F Montemurro, L Martincich, I Sarotto, I Bertotto, R Ponzone, L Cellini, ... European radiology 17, 1490-1497, 2007 | 79 | 2007 |
| Mitotic spindle assembly and genomic stability in breast cancer require PI3K-C2α scaffolding function F Gulluni, M Martini, MC De Santis, CC Campa, A Ghigo, JP Margaria, ... Cancer Cell 32 (4), 444-459. e7, 2017 | 77 | 2017 |
| Genomics to select treatment for patients with metastatic breast cancer F Andre, T Filleron, M Kamal, F Mosele, M Arnedos, F Dalenc, MP Sablin, ... Nature 610 (7931), 343-348, 2022 | 75 | 2022 |
